Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12516496 | 0.83 | ALDH1A1 (0.39) | GAAALDH1A1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL6893800 | 0.83 | TSHR (0.42) | TSHRSMN1; SMN2GAAMAPK1NR1H3 | |
| SCHEMBL12987377 | 0.81 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CA12 | |
| SCHEMBL3482928 | 0.81 | TSHR (0.45) | TSHRSMN1; SMN2GAAMAPK1NR1H3 | |
| SCHEMBL6895788 | 0.80 | CA12 (0.46) | TSHRSMN1; SMN2GAAMAPK1NR1H3 | |
| SCHEMBL3932127 | 0.79 | CHRNB2 (0.52) | TSHRSMN1; SMN2GAAMAPK1NR1H3 | |
| SCHEMBL24131729 | 0.79 | CHRNB2 (0.42) | TSHRSMN1; SMN2GAAMAPK1NR1H3 | |
| SCHEMBL19214797 | 0.79 | TSHR (0.39) | TSHRSMN1; SMN2GAAMAPK1NR1H3 | |
| SCHEMBL23125478 | 0.78 | CHRNB2 (0.34) | TSHRALDH1A1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL20095299 | 0.78 | CHRNB2 (0.41) | TSHRSMN1; SMN2GAAMAPK1NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780935-B2 | Mutant antibodies and conjugation thereof | PFIZER HEALTHCARE IRELAND (IE) | 2023-10-10 | — | — | US | disclosed |
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD (IE) | 2015-02-26 | — | — | US | disclosed |
| US-8912148-B2 | Methods of treating a disease or condition associated with abnormal angiogenesis | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2014-12-16 | — | — | US | disclosed |
| US-8741291-B2 | Multifunctional antibody conjugates | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2014-06-03 | — | — | US | disclosed |
| US-20120301431-A1 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD. | 2012-11-29 | — | — | US | disclosed |
| US-20120201809-A1 | MULTIFUNCTIONAL ANTIBODY CONJUGATES | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2012-08-09 | — | — | US | disclosed |
| US-20110087010-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2011-04-14 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| CN-1309699-C | Method and apparatus for preparing dialkyl carbonate | GEN ELECTRIC (US) | 2007-04-11 | — | — | CN | disclosed |
| CN-1678559-A | Method and apparatus for preparing a dialkyl carbonate | GEN ELECTRIC (US) | 2005-10-05 | — | — | CN | disclosed |
| EP-1562889-A1 | METHOD AND APPARATUS FOR PREPARING A DIALKYL CARBONATE | GENERAL ELECTRIC COMPANY (a New York Corporation) (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1419132-A1 | METHOD FOR PREPARING A DIALKYL CARBONATE, AND ITS USE IN THE PREPARATION OF DIARYL CARBONATES AND POLYCARBONATES | GENERAL ELECTRIC COMPANY (US) | 2004-05-19 | — | — | EP | disclosed |
| WO-2004000780-A1 | METHOD AND APPARATUS FOR PREPARING A DIALKYL CARBONATE | GENERAL ELECTRIC COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003016258-A1 | METHOD FOR PREPARING A DIALKYL CARBONATE, AND ITS USE IN THE PREPARATION OF DIARYL CARBONATES AND POLYCARBONATES | GENERAL ELECTRIC COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087010-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, KDR | TSHR 3656/4885SMN1; SMN2 3528/4885GAA 813/4885 |
| US-11780935-B2 | Mutant antibodies and conjugation thereof | IGLV6-57, IGSF11, F13B | TSHR 1745/4885SMN1; SMN2 2832/4885GAA 2394/4885 |
| US-20120301431-A1 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | VEGFA, FLT4, TEK | TSHR 2528/4885SMN1; SMN2 866/4885GAA 196/4885 |
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | VEGFA, TIE1, TEK | TSHR 3247/4885SMN1; SMN2 956/4885GAA 223/4885 |
| US-20120201809-A1 | MULTIFUNCTIONAL ANTIBODY CONJUGATES | CLTB, CLTA, FCGRT | TSHR 1911/4885SMN1; SMN2 4593/4885GAA 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.